Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.

Immunovia is a strategic center for translational cancer research in Lund, Sweden. Immunovia’s strategy is to decipher a large amount of information in the blood and translate it into clinically useful tools to diagnose complex diseases such as cancer and to do this earlier and more accurately than previously possible. Immunovia’s core technology platform, IMMray™, is based on antibody microarray analysis.

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

Provista Diagnostics is a Delaware company, develops and commercializes breakthrough, easy-to-administer blood-based diagnostic tests for early oncology-related disease state recognition and detection purposes. The Company's focus is on oncology-related diagnostics where a significantly high, unmet clinical need for such testing products exists. Near-term development and commercialization efforts focus on women's cancers such as breast and ovarian cancer. Provista Diagnostic’s technologies are developed at our CLIA accredited, GLP compliant, 13,610 sq/ft laboratory facility based in Scottsdale, Arizona. Recently, Provista has formed corporate headquarters in New York to take advantage of the sales, marketing, regulatory and financial expertise in the northeast US.

Vermilion, Inc. is an American private company located in Boulder, CO. The firm operates as an advertising agency specializes in audience research, brand development, web design & development services. It was founded by Bob Morehouse. Susan Touchette Aust is the current CEO, occupying that position since 1992.\nThe company says this about itself: Vermilion is a full-service, creative agency based in Boulder, Colorado, that provides distinctive and effective solutions exclusively to organizations that make a positive impact. As a Certified B Corporation, the agency is focused on helping purpose-driven brands grow and make a difference, supporting organizations advancing health and well-being, and connecting conservation and recreation in outdoor and environmental brands. Vermilion is also a Public Benefit Corporation, a specific type of corporation that allows for public benefit and social impact to be a charter purpose in addition to traditional corporate goals.

BioMarker Strategies LLC develops medicines for cancer. It provides cancer diagnostics system for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. The company was founded by Scott Allocco, Kathleen Murphy and Douglas P. Clark in May 2006 and is headquartered in Rockville, MD.

Hummingbird Diagnostics GmbH (doing business as Comprehensive Biomarker Center GmbH) is a private company headquartered in Heidelberg, Germany, that develops liquid biopsy diagnostics. It was founded by Jochen Kohlhaas and Karoly Nikolich. Jochen Kohlhaas is currently the CEO of the firm.\nThe company says this about itself: Hummingbird is harnessing the predictive power of blood-borne miRNAs to provide insights into human health and disease. Analyzing miRNAs with Hummingbird’s platform holds the potential for early disease detection, disease-specific prognostics, treatment response prediction, and the development of patient-centric therapies.

Provides diagnostic and therapeutic services for urological disorders

Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. Oncimmune LLC is a wholly-owned subsidiary of Oncimmune LTD based in Nottingham, England. The company is committed to advancing early cancer detection through proprietary autoantibody assay technologies based on biological technology initially identified by John Robertson, M.D., professor of surgery at Nottingham University, England, and chief scientific officer of Oncimmune LTD. Ongoing research and development is conducted by Oncimmune under the direction of Dr. Robertson. The company’s mission is to develop early cancer detection tests to identify more than 90 percent of solid-tumor cancers, which make up 70 percent of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. As a lab service, Oncimmune’s metro Kansas City laboratory is CLIA-certified under the Clinical Laboratory Improvements Amendment of 1988. Oncimmune LTD owns a portfolio of patents including No. 7,402,403 and No. 7,205,117.

Syn X Pharma, Inc. develops diagnostic and risk management test. The company was founded by Yahia A. Gawad and George Jackowski and is headquartered in Toronto, Canada.

EXINI Diagnostics provides advanced software for image analysis, targeted towards prostate cancer. EXINI’s technology was developed using unique image analysis derived from expert knowledge in medicine, image analysis, handling of large databases, and artificial neural networks.

febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany.

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.

ChemImage Corp. produces hyperspectral imaging instrumentation and software for chemical and biological applications. It offers analytical, instrumentation and training services. The firm serves the biomedical, forensics, pharmaceutical and threat detection markets. The company was founded by Patrick Treado in 1994 and is headquartered in Pittsburgh, PA.

OTraces Inc. is a provider of advanced oncology diagnostic systems. Manufactured in Nevada and Maryland USA, the company’s CDx Chemistry System™ elevates clinical blood analysis to new levels of precision and sophistication. Designed for cost-effective operation in the clinical laboratory, the company’s instrument group advances the science of cancer detection through the analysis of blood serum. The extreme sensitivity of protein detection possible with the CDx Chemistry System is combined with a proprietary bioinformatics engine for multi-marker profiling for the presence of cancer. The company’s first test kit – the BC Sera Dx™ panel for breast cancer detection and screening has completed Phase II of its validation in Russia with very successful results and after a small final validation protocol will be released in the fall of 2013. The prostate cancer test PC Sera Dx will under go validation also this fall. Test kits for additional cancers including ovarian, prostate, colon and lung are under development.

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

Applied Proteomics is a platform for discovering protein biomarkers that advances proteomics. It offers the application of proteomics in diagnostics and personalized medicine to improve healthcare outcomes. It develops a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems.

VeraLight is a medical device company that was established in October 2004 to focus on a comprehensive approach to non-invasive type 2 diabetes and pre-diabetes screening with the proprietary SCOUT DS® system. Their mission is to help stem the tide of the worldwide diabetes epidemic by driving early diabetes detection, thus enabling initiation of therapies that can prevent diabetes or reduce its complications. The company develops and acquires intellectual property, products, and services that contribute to this mission.